For almost two decades, RCPE – backed by TU Graz’s leading academic research – has advanced continuous pharmaceutical manufacturing. While this technology was originally developed to modernize and optimize pharmaceutical production, its strengths – speed, efficiency, and flexibility –  make it exceptionally well suited for rapid emergency medicine response and supply resilience.

RCPE’s Smart Stockpiling and Continuous Manufacturing

Traditional stockpiling enables quick access to vital medicines and is relatively straightforward to implement. Yet, it is expensive, space-intensive, limited by shelf life (2–3 years), and usually wastes valuable resources.

In a crisis, quick action is critical – getting medicines to patients in days or weeks, not the standard 9-12+ months of traditional pharma production processes. RCPE’s smart stockpiling uses compact containers to preserve pure APIs for more than 20 years, allowing for swift, efficient medicine production using advanced continuous manufacturing when needed most.

High-Level Delegation at RCPE

The visit brought together a distinguished group from the Federal Ministry of Defence, including Brigadier Rudolf Zauner (National Research Director) and Brigadier Martin Selzer (Adjutant to the Minister), alongside other senior leaders from the Ministry’s Department of Science, Research, and Development.

RCPE’s Business CEO, Thomas Klein, introduced the center, and Scientific CEO Prof. Johannes Khinast led the delegation through RCPE’s pilot plant, demonstrating the continuous tablet manufacturing line and facilities for highly potent active ingredients. This visit showcased RCPE’s capacity to turn scientific innovation into practical solutions for national resilience – and Minister Tanner demonstrated that the Austrian government is decisively taking medicine security into its own hands.